These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 38547904

  • 1. [Anti-CGRP-based Migraine Medications: A Comprehensive Overview].
    Triller P, Raffaelli B.
    Fortschr Neurol Psychiatr; 2024 Jul; 92(7-08):277-282. PubMed ID: 38547904
    [Abstract] [Full Text] [Related]

  • 2. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K, Michael RL, Rapoport AM.
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [Abstract] [Full Text] [Related]

  • 3. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P.
    Handb Clin Neurol; 2024 Jun; 199():107-124. PubMed ID: 38307640
    [Abstract] [Full Text] [Related]

  • 4. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ.
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [Abstract] [Full Text] [Related]

  • 5. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Nov; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 6. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L, Haanes KA, Warfvinge K, Krause DN.
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [Abstract] [Full Text] [Related]

  • 7. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
    Yuan H, White CS, Silberstein SD.
    Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic antibodies against CGRP or its receptor.
    Bigal ME, Walter S, Rapoport AM.
    Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
    Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.
    Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
    [Abstract] [Full Text] [Related]

  • 16. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R, Olesen J.
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [Abstract] [Full Text] [Related]

  • 17. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST, Wu JW.
    Prog Brain Res; 2020 Jun; 255():123-142. PubMed ID: 33008504
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G, Navarra P.
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.